# US 2013/0157997 A1 · Benzimidazole analogues for the treatment or prevention of flavivirus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157997 A1
- Document ID: US20130157997A1
- Status: Published application
- Kind: A1
- Application number: 13/678,854
- Filed: 2012-11-16
- Published: 2013-06-20
- Earliest claimed: 2009-07-16
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: James A. Henderson; John Maxwell; Louis Vaillancourt; Mark Morris; Ronald Grey, JR.; Simon Giroux; Laval Chan Chun Kong; Sanjoy Kumar Das; Bingan Liu; Carl Poisson; Caroline Cadilhac; Monica Bubenik; T. Jagadeeswar Reddy; Guy Falardeau; Constantin Yannopoulos; Jian Wang; Oswy Z. Pereira; Youssef L. Bennani; Albert C. Pierce; Govinda Rao Bhisetti; Kevin M. Cottrell; Valerie Marone
- Web page: https://patentgrep.com/patent/US20130157997A1

## CPC

- C07K 5/06052: {Val-amino acid}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 31/14: for RNA viruses
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 407/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 495/04: Ortho-condensed systems
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B′, X, Y, R1, R1′, R2, R2′, R3, R3′, R5, R5′, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

## Claims

### Claim 1

A compound of formula (IIIA):
or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B′ are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R1 is halogen, —ORa, —NRaRb, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, —P(═O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2′ and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, —(CH2)1-6OH, —ORa, —C(═O)ORa, NRaRb, —NRbC(═O)Ra, —C(O)NRaRb, —S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3′ are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
or a bond;
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C′;
R4 is H, C1-6 alkyl, or halogenated C1-6 alkyl;
R5 and R5′ are each independently halogen, —C(O)NRaRb, —(CH2)1-6OH, C1-6 alkyl, C1-6 halogenated alkyl, or C6-14 aryl; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12, wherein two occurrence of R4′ can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12, wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6′ are each independently H, C1-6 alkyl, —(CH2)1-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m and n, combined are 1, 2, 3 or 4;
p is 0, 1, 2, 3 or 4;
q′ is 0, 1 or 2;
q and r are each independently 0, 1, 2, 3 or 4;
R10 is halogen, —ORa, oxo, NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb;
R11 is halogen, —ORa, —NRaRb, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, —ORa, oxo, NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.

### Claim 2

(canceled)

### Claim 3

A compound of formula (IIB):
or pharmaceutically acceptable salts thereof, wherein
each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl;
B and B′ are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl;
R1 is halogen, —ORa, —NRaRb, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, —P(═O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12;
Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R2′, and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, —(CH2)1-6OH, —ORa, —C(═O)ORa, NRaRb, —NRbC(═O)Ra, —C(O)NRaRb, —S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl;
R3 and R3′ are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C2-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
X and Y are each independently
or a bond;
wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C′;
R4 is H, C1-6 alkyl, or halogenated C1-6 alky;
R5 and R5′ are each independently halogen, —NRaRb, —C(O)NRaRb, —(CH2)1-6OH, C1-6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12, wherein two occurrence of R4′ can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12, wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C2-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl;
R6 and R6′ are each independently H, C1-6 alkyl, —(CH2)1-6OH, C2-6 alkenyl, or C2-6 alkynyl;
m, and n, combined are 1, 2, 3 or 4;
p is 0, 1, 2, 3 or 4;
q′ is 0, 1 or 2;
q and r are each independently 0, 1, 2, 3 or 4;
R10 is halogen, —ORa, oxo, NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb;
R11 is halogen, —ORa, —NRaRb, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
R12 is halogen, —ORa, oxo, NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein each A is independently cyclopropyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperadinyl, phenyl, naphthalenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, thienopyrrolyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, or triazolyl; and wherein each A is independently substituted with (R1)p.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 4)

The compound according to claim 4, wherein each A is independently piperazinyl, piperadinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxolyl, benzothiazolyl, benzothiadiazolyl, benzothiophenyl, dihydrobenzodioxinyl, thienofuranyl, thienothienyl, quinolinyl, or triazolyl, each of which is substituted with (R1)p.

### Claim at position 7

-10. (canceled)

### Claim 11 (depends on 1)

The compound according to claim 1, wherein each A is independently a 5-12 membered heteroaryl wherein the heteroatom(s) are selected from the group consisting of oxygen and sulphur; wherein each A is independently substituted with (R1)p.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein B and B′ are independently absent, C1-6 alkyl or C2-6 alkynyl.

### Claim at position 10

-15. (canceled)

### Claim 16 (depends on 1)

The compound according to claim 1, wherein
is selected from the group consisting of:
and
t1+t2=p.

### Claim at position 12

-26. (canceled)

### Claim 27 (depends on 1)

The compound according to claim 1, wherein R1 is halogen, C1-4 alkyl which is unsubstituted or substituted one or more times by R10, —C(═O)ORa, —C(O)NRaRb, hydroxyl, cyano, or C1-3 alkoxy.

### Claim 28 (depends on 27)

The compound according to claim 27, wherein R1 is chloro, fluoro, bromo, methyl, ethyl, propyl, butyl, —CH2OH, difluoromethyl, trifluoromethyl, hydroxyl, cyano, or methoxy.

### Claim 29 (depends on 1)

The compound according to claim 1, wherein each R2′ are independently fluoro or methyl.

### Claim 30 (depends on 29)

The compound according to any one of claim 29, wherein q is 0.

### Claim 31 (depends on 1)

The compound according to claim 1, wherein each R2 are independently fluoro or methyl.

### Claim 32 (depends on 31)

The compound according to claim 31, wherein r is 0.

### Claim 33 (depends on 1)

The compound according to claim 1, wherein R6 and R6′ are H or methyl.

### Claim 34 (depends on 1)

The compound according to claim 1, wherein R5 and R5′ in formulas (IIB), (VIII), (IX), (X) and (XI), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, —CH2OH, —NRaNb, t-butoxy-, or hydroxyl; or two R5 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
two R5′ groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
and R5 and R5′ in formulas (IIIA), (IIIA′), (IVA) and (VA), are each independently halogen, methyl, ethyl, isopropyl, di-fluoromethyl, di-fluoroethyl, trifluoromethyl, tri-fluoroethyl, —CH2OH, —NRaNb, or t-butoxy-; or two R5 groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or
two R5′ groups together with the atoms to which they are attached form fused cyclopropyl, spiro cyclopropyl or

### Claim at position 21

-36. (canceled)

### Claim 37 (depends on 1)

The compound according to claim 1, wherein m and n are independently 1 or 2.

### Claim 38 (depends on 37)

The compound according to claim 37, wherein m and n are 1.

### Claim 39 (depends on 1)

The compound according to claim 1, wherein X and Y are

### Claim 40 (depends on 1)

The compound according to claim 1, wherein R3 and R3′ are each independently, C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, C7-8 aralkyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-8 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-8 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12.

### Claim at position 26

-45. (canceled)

### Claim 46 (depends on 1)

The compound according to claim 1, wherein R10 is halogen, —ORa, oxo, —NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, or —NRbSO2NRaRb, wherein Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl

### Claim at position 28

-48. (canceled)

### Claim 49 (depends on 1)

The compound according to claim 1, wherein Ra-Rd are each independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C7-8 aralkyl, 5-6 membered heteroaryl, 6-8 membered heteroaralkyl, 5-6 membered heterocycle, or 6-8 membered heterocycle-alkyl.

### Claim at position 30

-51. (canceled)

### Claim 52 (depends on 1)

The compound according to claim 1, wherein the compound is of formula (IVA):
or pharmaceutically acceptable salts thereof, wherein
R7 and R7′ are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8′ are each independently —NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —NRbSO2Ra, or —NRbSO2NRaRb, wherein Ra Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and
m and n combined are 0, 1, 2, 3 or 4.

### Claim at position 32

-58. (canceled)

### Claim 59 (depends on 1)

The compound according to claim 1, wherein the compound is of formula (VA):
or pharmaceutically acceptable salts thereof.

### Claim 60

(canceled)

### Claim 61 (depends on 59)

The compound of claim 59, wherein the compound is of formula (V):
or pharmaceutically acceptable salts thereof.

### Claim 62 (depends on 61)

The compound according to claim 61, wherein the compound is of formula (VI):
or pharmaceutically acceptable salts thereof.

### Claim at position 37

-65. (canceled)

### Claim 66 (depends on 1)

The compound according to claim 1, wherein the compound is of formula (VII):
or pharmaceutically acceptable salts thereof;
wherein
R2 and R2′ are each independently C1-8 alkyl which is unsubstituted or substituted one or more times by R10, C2-8 alkenyl which is unsubstituted or substituted one or more times by R10, C2-8 alkynyl which is unsubstituted or substituted one or more times by R10, phenyl which is unsubstituted or substituted one or more times by R11, benzyl which is unsubstituted or substituted one or more times by R11, 5-6 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-7 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-6 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-7 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12;
R8 and R8′ are each independently —NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —NRbSO2Ra, or —NRbSO2NRaRb, wherein Ra Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C2-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl.

### Claim at position 39

-161. (canceled)

### Claim 162 (depends on 1)

The compound according to claim 1, for treating or preventing a Hepatitis C viral infection in a human.

### Claim 163 (depends on 1)

A pharmaceutical composition comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.

### Claim at position 42

-168. (canceled)
